Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years

Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2022-01, Vol.17 (1), p.e0261124-e0261124
Hauptverfasser: Hemminki, Kari, Försti, Asta, Hemminki, Akseli, Ljungberg, Börje, Hemminki, Otto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e0261124
container_issue 1
container_start_page e0261124
container_title PloS one
container_volume 17
creator Hemminki, Kari
Försti, Asta
Hemminki, Akseli
Ljungberg, Börje
Hemminki, Otto
description Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database. Finland and Sweden are neighboring countries with largely similar health care systems but higher economic resources and health care expenditure in Sweden. We present results on 1- and 5-year relative survival rates, and additionally provide a novel measure, the difference between 1- and 5-year relative survival, indicating how well survival was maintained between these two periods. Over the 50-year period the median diagnostic age has increased by several years and the incidence in the very old patients has increased vastly. Relative 1- year survival rates increased until early 1990s in both countries, and with minor gains later reaching about 90% in men and 85% in women. Although 5-year survival also developed favorably until early 1990s, subsequent gains were small. Over time, age specific differences in male 1-year survival narrowed but remained wide in 5-year survival. For women, age differences were larger than for men. The limitations of the study were lack of information on treatment and stage. In conclusion, challenges are to improve 5-year survival, to reduce the gender gap and to target specific care to the most common patient group, those of 70 years at diagnosis. The most effective methods to achieve survival gains are to target control of tobacco use, emphasis on early diagnosis with prompt action at hematuria, upfront curative treatment and awareness of high relapse requiring regular cystoscopy follow up.
doi_str_mv 10.1371/journal.pone.0261124
format Article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2616581567</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A688645163</galeid><doaj_id>oai_doaj_org_article_5358b441b23c439aa74dbcde17920db7</doaj_id><sourcerecordid>A688645163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c730t-f8302e2636ccdb3432277c1141067af9cc13ead33721ee46bd36024680b3e4223</originalsourceid><addsrcrecordid>eNqNk11v0zAYhSMEYmPwDxBEQkJw0eKv2MkNUjUYVJo0icIuuLEc22ldpXZmxx379zhtNzVoF8iKbNnPOcp77DfLXkMwhZjBT2sXvRXttHNWTwGiECLyJDuFFUYTigB-erQ-yV6EsAagwCWlz7MTTKoSsQqfZr8X0W_NVrS5sXndCqW0z4VVeey6tIreWOHv8t4L2edSWKl9GNALY9sBG77FrVba5v3Ku7hc5QXI77Tw4WX2rBFt0K8O81n26-Lrz_Pvk8urb_Pz2eVEMgz6SVNigDSimEqpakwwQoxJCAkElImmkhJiLRTGDEGtCa0VpgARWoIaa4IQPsve7n271gV-iCXwlAgtSlhQloj5nlBOrHnnzSbVxJ0wfLfh_JIL3xvZal7goqwJgTXCkuBKCEZULZWGrEJA1YPXZO8VbnUX65HbF3M927nFTeSwgojRxH8-_F2sN1pJbVOW7Ug2PrFmxZduy0uGKGFlMvhwMPDuJurQ840JUrcpfu3ivs6qKPAOffcP-ngaB2opUsHGNm643cGUz2hZUlJAihM1fYRKQ-mNkenNNSbtjwQfR4LE9PpPvxQxBD5f_Ph_9up6zL4_YldatP0quDb2xtkwBskelN6F4HXzEDIEfGiZ-zT40DL80DJJ9ub4gh5E9z2C_wK2GA9u</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616581567</pqid></control><display><type>article</type><title>Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SWEPUB Freely available online</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Hemminki, Kari ; Försti, Asta ; Hemminki, Akseli ; Ljungberg, Börje ; Hemminki, Otto</creator><contributor>Roemer, Klaus</contributor><creatorcontrib>Hemminki, Kari ; Försti, Asta ; Hemminki, Akseli ; Ljungberg, Börje ; Hemminki, Otto ; Roemer, Klaus</creatorcontrib><description>Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database. Finland and Sweden are neighboring countries with largely similar health care systems but higher economic resources and health care expenditure in Sweden. We present results on 1- and 5-year relative survival rates, and additionally provide a novel measure, the difference between 1- and 5-year relative survival, indicating how well survival was maintained between these two periods. Over the 50-year period the median diagnostic age has increased by several years and the incidence in the very old patients has increased vastly. Relative 1- year survival rates increased until early 1990s in both countries, and with minor gains later reaching about 90% in men and 85% in women. Although 5-year survival also developed favorably until early 1990s, subsequent gains were small. Over time, age specific differences in male 1-year survival narrowed but remained wide in 5-year survival. For women, age differences were larger than for men. The limitations of the study were lack of information on treatment and stage. In conclusion, challenges are to improve 5-year survival, to reduce the gender gap and to target specific care to the most common patient group, those of 70 years at diagnosis. The most effective methods to achieve survival gains are to target control of tobacco use, emphasis on early diagnosis with prompt action at hematuria, upfront curative treatment and awareness of high relapse requiring regular cystoscopy follow up.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0261124</identifier><identifier>PMID: 34982793</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Age ; Age differences ; Age groups ; Aged ; Aged, 80 and over ; Bladder ; Bladder cancer ; Cancer ; Cancer survivors ; Cancer therapies ; Chemotherapy ; Databases, Factual ; Demographic aspects ; Diagnosis ; Epidemiology ; Female ; Finland - epidemiology ; Follow-Up Studies ; Gender aspects ; Gene therapy ; Health care ; Health services ; Hematuria ; Humans ; Immunology ; Incidence ; Male ; Medical diagnosis ; Medical prognosis ; Medical research ; Medicine and Health Sciences ; Men ; Middle Aged ; Patient outcomes ; Patients ; People and places ; Skin cancer ; Statistics ; Survival ; Survival Rate - trends ; Sweden - epidemiology ; Tobacco ; Tobacco Use ; Trends ; Tumors ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - epidemiology ; Urinary Bladder Neoplasms - mortality ; Urinary tract ; Urogenital system ; Urologic Neoplasms - diagnosis ; Urologic Neoplasms - epidemiology ; Urologic Neoplasms - mortality ; Urology ; Urothelial cancer ; Women</subject><ispartof>PloS one, 2022-01, Vol.17 (1), p.e0261124-e0261124</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Hemminki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Hemminki et al 2022 Hemminki et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c730t-f8302e2636ccdb3432277c1141067af9cc13ead33721ee46bd36024680b3e4223</citedby><cites>FETCH-LOGICAL-c730t-f8302e2636ccdb3432277c1141067af9cc13ead33721ee46bd36024680b3e4223</cites><orcidid>0000-0002-2769-3316</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726478/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726478/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,552,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34982793$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-191276$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><contributor>Roemer, Klaus</contributor><creatorcontrib>Hemminki, Kari</creatorcontrib><creatorcontrib>Försti, Asta</creatorcontrib><creatorcontrib>Hemminki, Akseli</creatorcontrib><creatorcontrib>Ljungberg, Börje</creatorcontrib><creatorcontrib>Hemminki, Otto</creatorcontrib><title>Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database. Finland and Sweden are neighboring countries with largely similar health care systems but higher economic resources and health care expenditure in Sweden. We present results on 1- and 5-year relative survival rates, and additionally provide a novel measure, the difference between 1- and 5-year relative survival, indicating how well survival was maintained between these two periods. Over the 50-year period the median diagnostic age has increased by several years and the incidence in the very old patients has increased vastly. Relative 1- year survival rates increased until early 1990s in both countries, and with minor gains later reaching about 90% in men and 85% in women. Although 5-year survival also developed favorably until early 1990s, subsequent gains were small. Over time, age specific differences in male 1-year survival narrowed but remained wide in 5-year survival. For women, age differences were larger than for men. The limitations of the study were lack of information on treatment and stage. In conclusion, challenges are to improve 5-year survival, to reduce the gender gap and to target specific care to the most common patient group, those of 70 years at diagnosis. The most effective methods to achieve survival gains are to target control of tobacco use, emphasis on early diagnosis with prompt action at hematuria, upfront curative treatment and awareness of high relapse requiring regular cystoscopy follow up.</description><subject>Age</subject><subject>Age differences</subject><subject>Age groups</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bladder</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Cancer survivors</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Databases, Factual</subject><subject>Demographic aspects</subject><subject>Diagnosis</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Finland - epidemiology</subject><subject>Follow-Up Studies</subject><subject>Gender aspects</subject><subject>Gene therapy</subject><subject>Health care</subject><subject>Health services</subject><subject>Hematuria</subject><subject>Humans</subject><subject>Immunology</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Men</subject><subject>Middle Aged</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>People and places</subject><subject>Skin cancer</subject><subject>Statistics</subject><subject>Survival</subject><subject>Survival Rate - trends</subject><subject>Sweden - epidemiology</subject><subject>Tobacco</subject><subject>Tobacco Use</subject><subject>Trends</subject><subject>Tumors</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - epidemiology</subject><subject>Urinary Bladder Neoplasms - mortality</subject><subject>Urinary tract</subject><subject>Urogenital system</subject><subject>Urologic Neoplasms - diagnosis</subject><subject>Urologic Neoplasms - epidemiology</subject><subject>Urologic Neoplasms - mortality</subject><subject>Urology</subject><subject>Urothelial cancer</subject><subject>Women</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>D8T</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11v0zAYhSMEYmPwDxBEQkJw0eKv2MkNUjUYVJo0icIuuLEc22ldpXZmxx379zhtNzVoF8iKbNnPOcp77DfLXkMwhZjBT2sXvRXttHNWTwGiECLyJDuFFUYTigB-erQ-yV6EsAagwCWlz7MTTKoSsQqfZr8X0W_NVrS5sXndCqW0z4VVeey6tIreWOHv8t4L2edSWKl9GNALY9sBG77FrVba5v3Ku7hc5QXI77Tw4WX2rBFt0K8O81n26-Lrz_Pvk8urb_Pz2eVEMgz6SVNigDSimEqpakwwQoxJCAkElImmkhJiLRTGDEGtCa0VpgARWoIaa4IQPsve7n271gV-iCXwlAgtSlhQloj5nlBOrHnnzSbVxJ0wfLfh_JIL3xvZal7goqwJgTXCkuBKCEZULZWGrEJA1YPXZO8VbnUX65HbF3M927nFTeSwgojRxH8-_F2sN1pJbVOW7Ug2PrFmxZduy0uGKGFlMvhwMPDuJurQ840JUrcpfu3ivs6qKPAOffcP-ngaB2opUsHGNm643cGUz2hZUlJAihM1fYRKQ-mNkenNNSbtjwQfR4LE9PpPvxQxBD5f_Ph_9up6zL4_YldatP0quDb2xtkwBskelN6F4HXzEDIEfGiZ-zT40DL80DJJ9ub4gh5E9z2C_wK2GA9u</recordid><startdate>20220104</startdate><enddate>20220104</enddate><creator>Hemminki, Kari</creator><creator>Försti, Asta</creator><creator>Hemminki, Akseli</creator><creator>Ljungberg, Börje</creator><creator>Hemminki, Otto</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>ADHXS</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>D93</scope><scope>ZZAVC</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2769-3316</orcidid></search><sort><creationdate>20220104</creationdate><title>Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years</title><author>Hemminki, Kari ; Försti, Asta ; Hemminki, Akseli ; Ljungberg, Börje ; Hemminki, Otto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c730t-f8302e2636ccdb3432277c1141067af9cc13ead33721ee46bd36024680b3e4223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>Age differences</topic><topic>Age groups</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bladder</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Cancer survivors</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Databases, Factual</topic><topic>Demographic aspects</topic><topic>Diagnosis</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Finland - epidemiology</topic><topic>Follow-Up Studies</topic><topic>Gender aspects</topic><topic>Gene therapy</topic><topic>Health care</topic><topic>Health services</topic><topic>Hematuria</topic><topic>Humans</topic><topic>Immunology</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Men</topic><topic>Middle Aged</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>People and places</topic><topic>Skin cancer</topic><topic>Statistics</topic><topic>Survival</topic><topic>Survival Rate - trends</topic><topic>Sweden - epidemiology</topic><topic>Tobacco</topic><topic>Tobacco Use</topic><topic>Trends</topic><topic>Tumors</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - epidemiology</topic><topic>Urinary Bladder Neoplasms - mortality</topic><topic>Urinary tract</topic><topic>Urogenital system</topic><topic>Urologic Neoplasms - diagnosis</topic><topic>Urologic Neoplasms - epidemiology</topic><topic>Urologic Neoplasms - mortality</topic><topic>Urology</topic><topic>Urothelial cancer</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hemminki, Kari</creatorcontrib><creatorcontrib>Försti, Asta</creatorcontrib><creatorcontrib>Hemminki, Akseli</creatorcontrib><creatorcontrib>Ljungberg, Börje</creatorcontrib><creatorcontrib>Hemminki, Otto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Umeå universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Umeå universitet</collection><collection>SwePub Articles full text</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hemminki, Kari</au><au>Försti, Asta</au><au>Hemminki, Akseli</au><au>Ljungberg, Börje</au><au>Hemminki, Otto</au><au>Roemer, Klaus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2022-01-04</date><risdate>2022</risdate><volume>17</volume><issue>1</issue><spage>e0261124</spage><epage>e0261124</epage><pages>e0261124-e0261124</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database. Finland and Sweden are neighboring countries with largely similar health care systems but higher economic resources and health care expenditure in Sweden. We present results on 1- and 5-year relative survival rates, and additionally provide a novel measure, the difference between 1- and 5-year relative survival, indicating how well survival was maintained between these two periods. Over the 50-year period the median diagnostic age has increased by several years and the incidence in the very old patients has increased vastly. Relative 1- year survival rates increased until early 1990s in both countries, and with minor gains later reaching about 90% in men and 85% in women. Although 5-year survival also developed favorably until early 1990s, subsequent gains were small. Over time, age specific differences in male 1-year survival narrowed but remained wide in 5-year survival. For women, age differences were larger than for men. The limitations of the study were lack of information on treatment and stage. In conclusion, challenges are to improve 5-year survival, to reduce the gender gap and to target specific care to the most common patient group, those of 70 years at diagnosis. The most effective methods to achieve survival gains are to target control of tobacco use, emphasis on early diagnosis with prompt action at hematuria, upfront curative treatment and awareness of high relapse requiring regular cystoscopy follow up.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>34982793</pmid><doi>10.1371/journal.pone.0261124</doi><tpages>e0261124</tpages><orcidid>https://orcid.org/0000-0002-2769-3316</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2022-01, Vol.17 (1), p.e0261124-e0261124
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2616581567
source MEDLINE; DOAJ Directory of Open Access Journals; SWEPUB Freely available online; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry
subjects Age
Age differences
Age groups
Aged
Aged, 80 and over
Bladder
Bladder cancer
Cancer
Cancer survivors
Cancer therapies
Chemotherapy
Databases, Factual
Demographic aspects
Diagnosis
Epidemiology
Female
Finland - epidemiology
Follow-Up Studies
Gender aspects
Gene therapy
Health care
Health services
Hematuria
Humans
Immunology
Incidence
Male
Medical diagnosis
Medical prognosis
Medical research
Medicine and Health Sciences
Men
Middle Aged
Patient outcomes
Patients
People and places
Skin cancer
Statistics
Survival
Survival Rate - trends
Sweden - epidemiology
Tobacco
Tobacco Use
Trends
Tumors
Urinary Bladder Neoplasms - diagnosis
Urinary Bladder Neoplasms - epidemiology
Urinary Bladder Neoplasms - mortality
Urinary tract
Urogenital system
Urologic Neoplasms - diagnosis
Urologic Neoplasms - epidemiology
Urologic Neoplasms - mortality
Urology
Urothelial cancer
Women
title Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T23%3A53%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20in%20bladder%20and%20upper%20urinary%20tract%20cancers%20in%20Finland%20and%20Sweden%20through%2050%20years&rft.jtitle=PloS%20one&rft.au=Hemminki,%20Kari&rft.date=2022-01-04&rft.volume=17&rft.issue=1&rft.spage=e0261124&rft.epage=e0261124&rft.pages=e0261124-e0261124&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0261124&rft_dat=%3Cgale_plos_%3EA688645163%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2616581567&rft_id=info:pmid/34982793&rft_galeid=A688645163&rft_doaj_id=oai_doaj_org_article_5358b441b23c439aa74dbcde17920db7&rfr_iscdi=true